PMR treatment with no oral steroids, low dose MTX and occasional steroid injections? Surprising and intriguing: little success previously in non-steroid paradigm in PMR, more data on this please, def worth further testing! Hospital 12 de Octubre, Madrid #ACR19 ABST0742 @RheumNow https://t.co/I15GA4gjPw

Takayasu's arteritis isn't just one, homogenous disease - and different phenotypes have different outcomes. Interesting from @petercgrayson's group at @NIH_NIAMS #ACR19 ABST0753 @RheumNow https://t.co/sWxUGaCRq2

You heard it from the oncologist- autoimmune disease is NOT an exclusion criterion for being treated with immune checkpoint inhibitors! Flare is common but manageable #ACR19

Here are the results of the poll. Thanks for participating. We look forward to more studies that will help us answer this important question 🤫 #ACR19 @RheumNow https://t.co/q3AJZS6spj

• Dr. Antoni Chan on Twitter: "Does anti-TNF treatment halt radiographc prog…

GiACTA What happened when weekly TCZ stopped? 42% maintained clinical remission on NO treatment at end 2yr Part2 What happened when Pred stopped (this happened in part1)? Taper 26wk: 32% no flare over yr Taper 52wk: 51% no flare over that yr #ACR19 @rheumnow Abst0808

GiACTA 1: blinded injections stopped wk52 Part 2: 2yrs Time to flare after remission Most flares in part 1 in those randomised to GC alone Lowest cumulative GC doses over 3y in TCZ-QW (50% less) #ACR19 @rheumnow Abst0808

GiACTA Part 1 at conclusion, different gps obvious: In remission no treatment In remission on treatment Recently active, on treatment GiACTA Part 2 Aims: Long term safety of TCZ-treated GCA Explore maintenance of efficacy after TCZ discontinuation #ACR19 @rheumnow Abst0808

FINCH3: in this cohort naive to MTX pre-trial, interesting that safety looks good! Maybe too early to tell #ACR19 @rheumnow Abst0927 #ACRbest https://t.co/QCdC8UQR3f

Fenebrutinib- Conclusions from phase2. How does this compare to our other small molecules? Will trial development continue? #ACR19 @rheumnow Abst0929 https://t.co/5ahkmSB11X

Awesome to hang out with my friends @psufka and @DrBhana to record an episode of ACR on Air on location at #ACR19 ! https://t.co/WeolRLGs17

25% of SLE and RA patients at this academic practice were receiving HCQ above recommended doses, by @SkorupaTara & @RobShmerling #ACR19 @rheumnow #Abstr #ACRBest https://t.co/pq379l9ZPH

Holy smokes! 18x higher risk of cardiovascular disease in Black SLE patients, highest at 1 and 10 years after diagnosis - Dr Shivani Garg    #ACR19 @rheumnow #Abstr  #ACRBest https://t.co/kXoMNu4QKb

A second study (after MAINRITSAN) showing the superiority of rituximab vs. azathioprine for maintenance of remission in ANCA-associated vasculitis, by Dr. Rona Smith #ACR19 @rheumnow #Abstr  #ACRBest https://t.co/H8VJiFhp6z

GCA is really a chronic disease, difficult to maintain remission off meds, regardless of initial treatment strategy. Findings from Part 2 of the GIACTA trial of tocilizumab for GCA. Dr. John Stone #ACR19 @rheumnow #Abstr  #ACRBest https://t.co/gxdQrH0pUj

BeSt for Kids study showed comparable efficacy of sequential monotherapy, MTX+pred, or MTX+Etanercept. However, many patients had TNFi added or TNFi switched to achieve inactive disease #ACR19 @rheumnow #Abstr  #ACRBest https://t.co/p5xdJznNhN